Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play

Aligos Therapeutics, Inc. (ALGS) announced an update on their ongoing clinical study.

This Phase 1 study, officially titled “A Phase 1 Non-Randomized, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function,” aims to see how the drug behaves in the body and how safe it is. The focus is on people with different levels of kidney function, which matters for long-term commercial use in chronic hepatitis B.

The study tests a single 100 mg oral dose of pevifoscorvir sodium, also known as ALG-000184. This drug is being developed to treat chronic hepatitis B, with the goal of offering a more effective and convenient antiviral option.

The trial is interventional and uses a non-randomized, parallel group design, meaning participants are assigned to groups based on kidney function instead of chance. It is open-label, so both doctors and participants know they are getting ALG-000184, and the main aim is to assess treatment safety and drug exposure.

One group includes subjects with renal impairment, while another includes those without renal issues, and both receive the same single dose and 14-day follow-up. This setup helps compare how the body handles the drug in each group, which is key for dosing rules if the drug reaches the market.

The study was first submitted on 2025-12-15, marking the formal move of this asset into a renal safety-focused Phase 1 program. The last update was submitted on 2026-02-26, and the trial is currently listed as recruiting, which signals active site work and ongoing patient enrollment.

Primary completion and full completion dates are not yet posted, so investors should assume readouts are still at least several quarters away. These dates will matter for timing of catalysts, as initial safety and dosing data can influence partnership talks and future capital needs.

For Aligos Therapeutics (ALGS), this update shows continued investment in ALG-000184 and supports its broader hepatitis B pipeline narrative. Clear renal safety could expand the eligible patient pool and support premium pricing, which would be positive for long-term valuation if later-stage efficacy data are strong.

Investor sentiment may improve modestly on confirmation that the study is recruiting and on schedule, especially after past volatility in small-cap biotech names. However, near-term stock moves will likely remain muted until the company provides concrete safety and pharmacokinetic data, while larger peers in hepatitis B keep the competitive bar high.

The study is ongoing and recently updated, and further operational and scientific details are available on the ClinicalTrials portal under identifier NCT07342881.

To learn more about ALGS’s potential, visit the Aligos Therapeutics, Inc. drug pipeline page.